If you want to see your investment in the biotech market grow two-fold, these are the top stocks to buy.
FDA announcements can make or break a stock. These four events are the most important ones this month.
Wall Street is optimistic about Teladoc's prospects. Should investors feel the same?
Positive trial results are always a good thing, but is this newly hyped stock worth it?
With new promising results for its diabetes drug, is Sanofi a good investment right now?
Analysts think the sky's the limit for Sorrento. Are they right?
Why are analysts so bullish on this small-cap biotech stock, and are they justified?
Following strong results for its flagship CTX001 drug, should you add CRISPR to your portfolio?
Relugolix has the potential to be a blockbuster drug in two markets, but it faces competition in both.
There's a strong case to be made that Aphria is the new king of the Canadian cannabis playground.
History is littered with promising phase 2 drugs that failed upon further testing. Investors shouldn't get caught up in the hype.
What should investors think of this promising biotech stock and its pruritus drug candidate?
Could this tarnished pot stock possibly stage a turnaround? Most don't think so.
Is the optimism surrounding this insulin pump maker justified?
Livongo might be up after beating expectations, but does that make this stock an automatic buy?
What should investors think of Sientra after its impressive Q3 results?
Which of these two cannabis companies will reign supreme in the future?
While good publicity for the cannabis industry, how big of a deal is this for Canopy Growth?
Prospects for Amarin's omega-3 drug seem strong, but does that make the stock a buy?
There are some highly promising diabetes treatments entering the market that investors should know about.